Ranbaxy Laboratories Limited (hereafter, Ranbaxy), a subsidiary of bcゲーム 初回入金ボーナスankyo Co., Ltd. (hereafter, bcゲーム 初回入金ボーナスankyo), announced on May 22 the actions that Ranbaxy has taken in recent years to address past conduct under prior management (http://www.daiichisankyo.com/media_investors/media_relations/press_releases/index.html).
DaiichiSankyo continues to support Ranbaxy in its efforts to address and correct the conduct of the past which led to the investigations by the U.S. Department of Justice ("DOJ") and the U.S. Food and Drug Administration ("USFDA"). These efforts include significant changes to Ranbaxy's management, culture, operations and compliance.
bcゲーム 初回入金ボーナスankyo believes that certain former shareholders of Ranbaxy concealed and misrepresented critical information concerning the U.S. DOJ and FDA investigations. bcゲーム 初回入金ボーナスankyo is currently pursuing its available legal remedies and cannot comment further on the subject at this time.
About bcゲーム 初回入金ボーナスankyo Co., Ltd.
Listed: Code No.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges
President and CEO: Joji Nakayama
「つながる特許庁 in 宮古島」2025/2/26(水)開催！2025.01.23 10:00
